Stem cell therapy can safely slow progression of relapsing-remitting MS
No evidence of disease activity in two thirds of those treated over 10 years Should be considered standard care for highly active disease, say researchers ...
No evidence of disease activity in two thirds of those treated over 10 years Should be considered standard care for highly active disease, say researchers ...